NCT03946111View on ClinicalTrials.gov

Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Medication Change for Non-Responders

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

August 7, 2019

Primary Completion Date

December 5, 2024

Study Completion Date

December 5, 2024

Conditions
Binge-Eating DisorderObesity
Interventions
DRUG

Naltrexone and Bupropion

Participants randomly assigned to this arm will receive 12 weeks of Naltrexone and Bupropion medication.

OTHER

Placebo

Participants randomly assigned to this arm will receive 12 weeks of an inactive placebo.

Trial Locations (1)

06510

Yale Department of Psychiatry, New Haven

All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

Yale University

OTHER

NCT03946111 - Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Medication Change for Non-Responders | Biotech Hunter | Biotech Hunter